Status:
COMPLETED
Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy
Lead Sponsor:
Seoul National University Hospital
Conditions:
Carcinoma, Ductal, Breast
Invasive Breast Cancer
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
It is considered that whether or not the accompanying invasive cancer classified through MRI images of breast cancer patients identified as Ductal Carcinoma in situ (DCIS) through preoperative tissue ...
Detailed Description
1. To date, there is no significant research data on the value of the Apparent Diffusion Coefficient (ADC) that can distinguish between pure Ductal Carcinoma in situ (pure DCIS) and invasive cancer (D...
Eligibility Criteria
Inclusion
- Adult over 19 years-old
- Breast Ductal Carcinoma in-situ patients who diagnosed preoperative tissue biopsy
- A person who understands this study and agrees with willingness to participate
Exclusion
- Ductal Carcinoma in-situ which diagnosed excisional biopsy
- When there is no lesion that can be discriminated from magnetic resonance imaging
- Neoadjuvant chemotherapy patients
- Patients who have complication (hematoma, abscess etc.) after preoperative biopsy
Key Trial Info
Start Date :
July 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2021
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT04498611
Start Date
July 13 2020
End Date
August 15 2021
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Jongno-gu, South Korea, 03080